Guggenheim lowered the firm’s price target on Sarepta (SRPT) to $112 from $150 and keeps a Buy rating on the shares. The firm, in its preview of Q1 earnings for 36 commercial-stage companies in its biotechnology coverage, revised some estimates to account for recent news flow, company commentary, and/or prescription trends.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target lowered to $184 from $215 at Oppenheimer
- Positive Outlook for Sarepta Therapeutics Amid Favorable Trial Evaluations and Proactive Regulatory Response
- Sarepta announces EU regulators temporarily halted dosing of ELEVIDYS
- H.C. Wainwright sees increased uncertainty for Sarepta franchise
- 3 Best Value Stocks to Buy Now, 4/4/2025, According to Analysts